Back
  1. Home
  2. Profile of Marilène BINSFELD (ULiège)
Profil

BINSFELD Marilène

Unilab > Laboratoire immuno - hématologie banque du sang

See author's contact details
Main Referenced Co-authors
Beguin, Yves  (43)
Caers, Jo  (38)
Baron, Frédéric  (28)
Hannon, Muriel  (22)
Heusschen, Roy  (18)
Main Referenced Keywords
multiple myeloma (11); bone disease (7); GVHD (6); saracatinib (6); SRC kinase (6);
Main Referenced Unit & Research Centers
GIGA-I3 - Giga-Infection, Immunity and Inflammation - ULiège (4)
Main Referenced Disciplines
Hematology (31)
Biochemistry, biophysics & molecular biology (13)
Immunology & infectious disease (4)

Publications (total 47)

The most downloaded
2071 downloads
CAERS, J., Binsfeld, M., Muller, J., Heusschen, R., & Beguin, Y. (2014). Gammapathie monoclonale de signification indéterminée : information destinée aux médecins référents. Revue Médicale de Liège, 69, 41-46. https://hdl.handle.net/2268/172664

The most cited

122 citations (OpenAlex)

Jörg, S., Grohme, D., Erzler, M., BINSFELD, M., Haghikia, A., Müller, D., Linker, R., & Kleinewietfeld, M. (04 August 2016). Environmental factors in autoimmune diseases and their role in multiple sclerosis. Cellular and Molecular Life Sciences, 73 (24), 4611-4622. doi:10.1007/s00018-016-2311-1 https://hdl.handle.net/2268/203684

Schmitz, L., Pirotte, M., Lebeau, A., Ernst, M., Fillet, M., DEVEY, A., SCHMITT, J., Cobraiville, G., BINSFELD, M., Gofflot, S., Beguin, Y.* , & Vertenoeil, G.*. (2023). Alterations of erythropoiesis in Covid-19 patients: prevalence of positive Coombs tests and iron metabolism. Therapeutic Advances in Hematology, 14, 20406207231199837. doi:10.1177/20406207231199837
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

BINSFELD, M., GOTHOT, A., & MONFORT, M. (02 February 2018). Detection of RhCE phenotypic variants by serologic routine blood grouping [Poster presentation]. 33rd General Annual Meeting of the Belgian Hematology Society, La Hulpe, Belgium.

Muller, J., BINSFELD, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (2017). Galectin-1 decreases during osteoclast formation [Poster presentation]. 44th Annual European Calcified Tissue Society Congress, Austria.

Belle, L.* , Fransolet, G.* , Somja, J., BINSFELD, M., Delvenne, P., Drion, P., Hannon, M., BEGUIN, Y., Ehx, G.* , & Baron, F.*. (12 December 2016). Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease. PLoS ONE, 11, 0167997. doi:10.1371/journal.pone.0167997
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Fransolet, G., Belle, L., SOMJA, J., DELVENNE, P., Hannon, M., Drion, P., BINSFELD, M., BEGUIN, Y., Ehx, G., & Baron, F. (08 December 2016). Limited impact of imatinib in a murine model of sclerodermatous chronic graft-versus-host disease (scl-cGVHD) [Paper presentation]. Séminaire des chercheurs Télévie 2017, Bruxelles, Belgium.

Belle, L., Fransolet, G., SOMJA, J., BINSFELD, M., DELVENNE, P., Drion, P., Hannon, M., BEGUIN, Y., Ehx, G., & Baron, F. (17 November 2016). Limited impact of imatinib in a murine model of sclerodermic chronic graft-versus-host disease [Poster presentation]. 16ème congrès de la Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) en commun avec la SFBCT, Liège, Belgium.

Jörg, S., Grohme, D., Erzler, M., BINSFELD, M., Haghikia, A., Müller, D., Linker, R., & Kleinewietfeld, M. (04 August 2016). Environmental factors in autoimmune diseases and their role in multiple sclerosis. Cellular and Molecular Life Sciences, 73 (24), 4611-4622. doi:10.1007/s00018-016-2311-1
Peer Reviewed verified by ORBi

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (28 February 2016). Galectin-1 is involved in osteoclast biology [Poster presentation]. 2nd Herbert Fleisch Workshop, Brugge, Belgium.

Binsfeld, M. (2016). Contribution to the study of immune characteristics in multiple myeloma [Doctoral thesis, Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/315244

Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. Belgian Journal of Hematology.
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). The Src Inhibitor AZD0530 Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma [Poster presentation]. 43rd Annual European Calcified Tissue Society Congress, Rome, Italy.

Binsfeld, M., Muller, J., Lamour, V., De Veirman, K., De Raeve, H., Bellahcene, A., Van Valckenborgh, E., BARON, F., BEGUIN, Y., CAERS, J., & Heusschen, R. (2016). Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. Oncotarget, 7, 37931-37943. doi:10.18632/oncotarget.9270
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma [Poster presentation]. GIGA day 2016, Liège, Belgium.

Heusschen, R.* , Muller, J.* , Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., BEGUIN, Y., Menu, E., Cohen-Solal, M., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma. Oncotarget, 7, 30712-30729. doi:10.18632/oncotarget.8750
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma [Paper presentation]. 31st General Annual Meeting of the Belgian Hematological Society, Brussels, Belgium.

BINSFELD, M., Hannon, M., Humblet-Baron, S., Beguin, Y., Baron, F., & CAERS, J. (30 January 2015). Effects of the immunomodulating peptide thymosin alpha 1 in multiple myeloma and immune reconstitution after hematopoietic stem cell transplantation in murine models [Poster presentation]. 30th General Annual Meeting of the Belgian Hematology Society, La Hulpe, Belgium.

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma. Blood.
Peer Reviewed verified by ORBi

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., Beguin, Y., Heusschen, R., & CAERS, J. (2015). The anti-angiogenic peptide Anginex blocks osteoclastogenesis. Belgian Journal of Hematology, Abstracts book.
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma. Blood, 126 (23), 3018.
Peer Reviewed verified by ORBi

Tangen, J.-M., Tierens, A., CAERS, J., BINSFELD, M., Olstad, O. K., Troseid, A.-M. S., Wang, J., Tjonnfjord, G. E., & Hetland, G. (January 2015). Immunomodulatory Effects of the Agaricus blazei Murrill-Based Mushroom Extract AndoSan in Patients with Multiple Myeloma Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation: A Randomized, Double Blinded Clinical Study. BioMed Research International, 2015, 718539. doi:10.1155/2015/718539
Peer Reviewed verified by ORBi

Binsfeld, M., HANNON, M., Otjacques, E., Humblet-Baron, S., BAUDOUX, E., BEGUIN, Y., BARON, F., & CAERS, J. (2015). Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation. Cancer Immunology, Immunotherapy, 64, 989-998. doi:10.1007/s00262-015-1708-2
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma [Poster presentation]. 57th ASH Annual Meeting and Exposition, Orlando, United States - Florida.

Binsfeld, M., Beguin, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Heusschen, R., Drion, P., Zilberberg, J., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS ONE, 113764. doi:10.1371/journal.pone.0113764
Peer Reviewed verified by ORBi

Binsfeld, M., Fostier, K., Muller, J., Baron, F., Schots, R., Beguin, Y., Heusschen, R., & CAERS, J. (2014). Cellular immunotherapy in multiple myeloma : lessons from preclinical models. Biochimica et Biophysica Acta. Reviews on Cancer, 1846, 392-404. doi:10.1016/j.bbcan.2014.08.001
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Thijssen, V., BEGUIN, Y., & CAERS, J. (2014). Galectin expression in the multiple myeloma microenvironment [Poster presentation]. GIGA day 2014, Liège, Belgium.

CAERS, J., Binsfeld, M., Muller, J., Heusschen, R., & Beguin, Y. (2014). Gammapathie monoclonale de signification indéterminée : information destinée aux médecins référents. Revue Médicale de Liège, 69, 41-46.
Peer reviewed

Binsfeld, M., Heusschen, R., Lamour, V., Van Valckenborgh, E., Bellahcene, A., Baron, F., BEGUIN, Y., & CAERS, J. (2014). Multiple myeloma cells instruct myeloid-derived suppressor cells to release pro-angiogenic cytokines. Belgian Journal of Hematology.

Binsfeld, M., BEGUIN, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Drion, P., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. Belgian Journal of Hematology.

Muller, J., CAERS, J., Binsfeld, M., Dubois, S., Carmeliet, G., BEGUIN, Y., & Heusschen, R. (2014). Galectin expression in the multiple myeloma microenvironment. Belgian Journal of Hematology.
Peer Reviewed verified by ORBi

Belle, L., Ehx, G., SOMJA, J., Binsfeld, M., HANNON, M., CAERS, J., Fransolet, G., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (December 2013). Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease [Poster presentation]. 55th Annual Meeting of the American Society of Hematology.

Belle, L., Ehx, G., SOMJA, J., BINSFELD, M., Hannon, M., Caers, J., Fransolet, G., Beguin, Y., Humblet-Baron, S., & Baron, F. (December 2013). Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease. Blood, 122 (21), 4474.
Peer Reviewed verified by ORBi

Binsfeld, M., BEGUIN, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Drion, P., Bogen, B., BARON, F., & CAERS, J. (April 2013). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation [Poster presentation]. 3rd International Conference "Cancer Immunotherapy and Immunomonitoring (CITIM)", Cracovie, Poland.

Belle, L., BINSFELD, M., DUBOIS, S., Hannon, M., Caers, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (February 2013). Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin. Biology of Blood and Marrow Transplantation, 19, 317.
Peer Reviewed verified by ORBi

Belle, L., Binsfeld, M., HANNON, M., CAERS, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (2013). Combination of Regulatory T Cells Injection with Rapamycin for Treatment of Chronic Graft-versus-Host Disease. Belgian Journal of Hematology.
Peer Reviewed verified by ORBi

Otjacques, E., Binsfeld, M., Beguin, Y., Noël, A., Cataldo, D., & CAERS, J. (2013). Aspects biologiques de l'angiogenèse dans le myélome multiple. Oncohématologie, 7 (2), 6-12.
Peer reviewed

Otjacques, E., Binsfeld, M., Rocks, N., Blacher, S., Vanderkerken, K., Noël, A., Beguin, Y., Cataldo, D., & CAERS, J. (2013). Mithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors. PLoS ONE, 8 (5), 62818. doi:10.1371/journal.pone.0062818
Peer Reviewed verified by ORBi

Belle, L., Binsfeld, M., Dubois, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (2013). Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin [Poster presentation]. BMT Tandem Meetings (ASBMT), Salt Lake City, United States.

Belle, L., Binsfeld, M., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & BARON, F. (2013). Combination of Regulatory T Cells Injection with Rapamycin for Treatment of Chronic Graft-versus-Host Disease [Paper presentation]. 28th General Meeting of the Belgian Hematological Society.

Hannon, M., Humblet-Baron, S., Graux, C., Maertens, J., Kerre, T., Theunissen, K., Daulne, C., Willems, E., Belle, L., Binsfeld, M., Gothot, A., Beguin, Y., & Baron, F. (2013). Comparison of Immune Reconstitution after Hematopoietic Stem Cell Transplantation with Flu-TBI versus TLI-ATG Conditioning. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 38.

Binsfeld, M., Otjacques, E., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & CAERS, J. (2013). The Immunomodulating Peptide Thymosin Alpha 1 Has no Effect on Multiple Myeloma Evolution and on Immune Reconstitution. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 41.

Belle, L., BINSFELD, M., Dubois, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humbelt-Baron, S., & BARON, F. (April 2012). Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice. Bone Marrow Transplantation, 47 Suppl 1.
Peer Reviewed verified by ORBi

Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., Briquet, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice [Paper presentation]. 38th EBMT Annual Meeting.

Hannon, M., Humblet-Baron, S., Graux, C., Maertens, J., Kerre, T., Theunissen, K., Daulne, C., Willems, E., Belle, L., Binsfeld, M., Gothot, A., Beguin, Y., & Baron, F. (2012). Comparison of Immune Reconstitution after Hematopoietic Stem Cell Transplantation with Flu-TBI versus TLI-ATG Conditioning. Haematologica, 97 (Supplement 1), 180.
Peer Reviewed verified by ORBi

Binsfeld, M., Belle, L., Hannon, M., Hofgaard, Dubois, S., Otjacques, E., BEGUIN, Y., Bogen, BARON, F., & CAERS, J. (2012). Adaptation of a murine chronic GvH model to study graftversus- myeloma effect after allogeneic transplantation. Bone Marrow Transplantation, 47 (Suppl.1).
Peer Reviewed verified by ORBi

Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin Prevents Experimental Sclerodermatous Chronic Graft-versus-Host Disease in mice [Paper presentation]. 27th General Meeting of the Belgian Hematological Society.

Binsfeld, M., Belle, L., Hannon, M., DUBOIS, S., Otjacques, E., Beguin, Y., Baron, F., & CAERS, J. (2012). Adaptation of a Murine Chronic GVH Model to Study Graft versus Myeloma Effect after Allogeneic Transplantation. Belgian Journal of Hematology, Abstracts book (Supplement of 27th General Meeting of the Belgian Hematological Society), 16.

Otjacques, E., Binsfeld, M., Noël, A., Beguin, Y., Cataldo, D., & CAERS, J. (2011). Biological aspects of angiogenesis in multiple myeloma. International Journal of Hematology, 94 (6), 505-18. doi:10.1007/s12185-011-0963-z
Peer Reviewed verified by ORBi

Contact ORBi